On October 19, 2011, Abbott Laboratories (NYSE: ABT) announced its plan to separate into two independent publicly traded companies. The spin company, a research-based pharmaceutical company to be named AbbVie Inc., will control ABT’s current portfolio of proprietary pharmaceuticals and biologics. The parent, a diversified medical products company, will retain the Abbott name. Miles White, the current Chairman and CEO, will remain in his roles at the parent company following the transaction, while Richard Gonzalez will transition from his role as current Vice President of Global Pharmaceuticals to Chairman and CEO of AbbVie. The spin-off will be conducted via a tax-free distribution to shareholders, which is expected to be completed in 2012. Capital and liability allocations are yet to be finalized. The spin-off will require SEC approval and an affirmative IRS ruling. AbbVie intends to list its shares on the NYSE under the symbol ‘ABBV’. It is expected that both entities will initially pay dividends, the sum of which will be equal to ABT’s current $2.04 per share annual payment.
AbbVie generated revenue of $17 billion in 2011, has a portfolio of leading medicines across a wide array of diseases and over 20 drugs in either Phase II or Phase III development in its pipeline. Sales will be mostly concentrated in developed markets. Patent expirations and an uncertain regulatory environment present the greatest risks to the spin company, but its drug pipeline appears healthy. This business, which has higher margins than the parent, should generate significant cash flow through at least 2016, when the patent for its largest patent-protected product expires.
The parent company generated revenue of $22 billion in 2011 from its established pharmaceuticals (branded generics outside of the US), nutritional products, and medical devices. Following the separation, ABT will have a more international focus, with approximately 40% of sales coming from emerging markets. ABT’s focus on selling existing products to new markets is expected to produce double-digit EPS growth rates, while a pipeline of new products and technologies could further expand margins. Acquisitions have spurred recent growth and may be an attractive strategy to increase the company’s global footprint and allow it to stay competitive in generics.
It could be suggested that the current size of ABT’s business, with a market capitalization in excess of $100 billion, makes it difficult to increase returns through the traditional drug development process. Even if ABT were to develop a blockbuster drug, the increase in sales and earnings might be only marginal in the context of the larger company. However, once the businesses are separated, new pharmaceutical developments could have an increased impact on growth rates and margins.
Additionally, it should be noted that the two businesses have differing margin and risk profiles. Operating margins of 40% for the proprietary pharmaceutical business may be at risk due to the changing regulatory landscape, so the market may be assigning an unwarranted risk discount to the non-pharma business. ABT currently trades slightly above the level of larger pharmaceutical drug makers but at a discount to a peer group of generic drug manufacturers. Upon separation, the net impact of a larger multiple on the parent should be offset by the effect of a multiple contraction on AbbVie. On a sum-of-the-parts basis, a fair value estimate of $64 is derived, attributing $27 per share to post-spin Abbott Laboratories and $37 per share to AbbVie. Given that ABT currently trades above this estimate, the shares are not recommended for purchase ahead of the spin-off.